2026 Q1 Portfolio Activity
In 2026 Q1, Davern Capital Partners, LP maintained a portfolio of 18 distinct positions. The most significant new addition was INSMED INC, now representing 8.19% of the total fund value. They heavily accumulated shares in ELI LILLY & CO, increasing the position by 228.4%. The fund also reduced its exposure to PFIZER INC by 22.0%.
Position History
hover any row below to update
Loading…
Total Positions
18
Quarter
2026 Q1
Top Holding
PFE (12.3%)
Top 10 Concentration
80.7%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-18 of 18
Davern Capital Partners, LP Full Holdings List — 2026 Q1
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
PFE
PFIZER INC
|
Healthcare | 12.28% | 16.44% |
#1
Prev: #1
|
6.0 |
—
|
-448,300 | -22.0% |
P
S
|
1,593,942 | $44,757,891 |
$24.09
+6.5%
|
2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | ||
|
REGN
REGENERON PHARM...
|
Healthcare | 9.50% | 13.08% |
#2
Prev: #2
|
5.8 |
—
|
-7,620 | -14.5% |
P
S
|
44,800 | $34,614,272 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
INSM
INSMED INC
|
Healthcare | 8.19% | — |
#3
Prev: #—
|
7.8 |
—
|
182,562 | — |
NEW
|
182,562 | $29,852,538 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
IONS
IONIS PHARMACEU...
|
Healthcare | 7.97% | 6.10% |
#4
4
Prev: #8
|
6.7 |
—
|
148,426 | 62.2% |
P
S
|
386,903 | $29,052,546 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
NTRA
NATERA INC
|
Healthcare | 7.90% | 5.83% |
#5
4
Prev: #9
|
6.7 |
—
|
65,316 | 83.0% |
P
S
|
143,966 | $28,791,760 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
BNTX
BIONTECH SE
|
Healthcare | 7.44% | 11.43% |
#6
3
Prev: #3
|
3.5 |
—
|
-66,161 | -17.8% |
P
S
|
305,055 | $27,113,288 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
ARGX
ARGENX SE
|
Healthcare | 7.02% | 9.70% |
#7
2
Prev: #5
|
3.3 |
—
|
-640 | -1.8% |
P
S
|
35,045 | $25,591,611 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
LLY
ELI LILLY & CO
|
Healthcare | 6.88% | 2.89% |
#8
2
Prev: #10
|
5.8 |
—
|
18,972 | 228.4% |
P
S
|
27,279 | $25,090,406 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
RPRX
ROYALTY PHARMA ...
|
Healthcare | 6.84% | 10.50% |
#9
5
Prev: #4
|
2.7 |
—
|
-320,641 | -38.1% |
P
S
|
520,009 | $24,944,832 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
ROIV
ROIVANT SCIENCE...
|
Healthcare | 6.64% | 7.21% |
#10
3
Prev: #7
|
3.2 |
—
|
-154,900 | -15.1% |
P
S
|
873,398 | $24,193,125 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
LEGN
LEGEND BIOTECH ...
|
Healthcare | 6.52% | 7.43% |
#11
5
Prev: #6
|
5.1 |
—
|
258,080 | 24.4% |
P
S
|
1,314,748 | $23,783,791 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
MLYS
MINERALYS THERA...
|
Healthcare | 3.32% | 2.47% |
#12
Prev: #12
|
4.3 |
—
|
236,505 | 112.3% |
P
S
|
447,153 | $12,113,375 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
ABVX
ABIVAX SA
|
Healthcare | 2.39% | 2.11% |
#13
1
Prev: #14
|
4.0 |
—
|
29,623 | 61.1% |
P
S
|
78,125 | $8,699,219 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
N/A
GENERATE BIOMED...
|
|
Unknown | 2.03% | — |
#14
Prev: #—
|
4.3 |
—
|
591,800 | — |
NEW
|
591,800 | $7,397,500 | — | 13F Filing | 2026-03-31 | 2026-05-14 | ||
|
PRCT
PROCEPT BIOROBO...
|
Healthcare | 1.79% | — |
#15
Prev: #—
|
4.2 |
—
|
261,200 | — |
NEW
|
261,200 | $6,532,612 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
GPCR
STRUCTURE THERA...
|
Healthcare | 1.67% | — |
#16
Prev: #—
|
4.2 |
—
|
126,461 | — |
NEW
|
126,461 | $6,095,420 | 2026 Q1 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
VRDN
VIRIDIAN THERAP...
|
Healthcare | 1.62% | 2.63% |
#17
6
Prev: #11
|
2.6 |
—
|
40,842 | 15.6% |
P
S
|
302,457 | $5,916,059 | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 | |||
|
CGON
CG ONCOLOGY INC
|
Healthcare | 0.00% | 2.17% |
Sold All 😨
(Was: #13) |
0.0 |
—
|
-162,005 | -100.0% |
CLOSED
|
— | $— | 2025 Q4 | 13F Filing | 2026-03-31 | 2026-05-14 |
Showing 1-18 of 18 holdings